TRIGO-GROUP
15.5.2019 10:02:07 CEST | Business Wire | Press release
TRIGO Group, a global leader of quality solutions for the transportation industry has acquired EMC Consulting, a top Romanian quality training company. By combining expertise, the merge aims to spear-head quality improvements for customers’ production processes.
TRIGO has served more than 8,000 customers over the past 22 years worldwide. Over the past 12 years, EMC Consulting has served over 50 multinational companies in Romania. Our partnership enables EMC Consulting to extend its market reach beyond Romania to more than 25 countries serviced by TRIGO. In addition, TRIGO’s experience is further enhanced by EMC Consulting’s extensive training portfolio and local expertise.
EMC Consulting is highly regarded within the manufacturing market. They have trained more than 5,000 people in 35 training courses, covering both theoretical and practical quality knowledge including manufacturing, logistics, continuous improvement, and project management. Their client portfolio includes key players in the automotive industry, such as IRUM, Continental, and Adient.
Ovidiu Veghes, Country Manager for TRIGO Romania, worked closely in finalizing the acquisition. He stated, “EMC Consulting fits perfectly with our service portfolio. Our customer collaborations will be further strengthened.”
Constantin Pătășanu, CEO of EMC Consulting, said, “I am convinced that our common goals will speed up our development. I am excited to utilize our quality knowledge with TRIGO and offer more diverse services made up of training and consultancy aspects.”
Zsolt Puskás, EVP of the TREQ division which oversees training and consultancy operations for TRIGO, commented, “EMC Consulting distinguishes itself by going beyond standard quality requirements, providing solutions that embrace adaptability and creativity. They are a proven group of experts improving the effectiveness of production.”
About EMC Consulting
Founded in 2007, EMC Consulting is a training and consulting company with certified trainers and consultants according to IATF, ISO, VDA, REFA, and PMI. Their portfolio includes topics like lean manufacturing, lean six sigma, process engineering and logistics management. They support organizations in finding simple, creative, and customized quality solutions. Visit: https://emctm.ro
About TRIGO Group
Founded in 1997, TRIGO Group is a Global Quality Solutions provider for the transportation sector, focused on automotive and aerospace industries. With more than 10,000 professionals present in 25 countries, TRIGO offers a comprehensive portfolio of services including quality engineering, rework, inspection, auditing, training, consulting, and project management. Visit: https://trigo-group.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20190515005054/en/
Contact:
Elaine Regas EVP, Global Sales & Marketing elaine.regas@trigo-group.com
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release
If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release
Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use
DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release
-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom